Search - tctmd.com

Displaying 221 - 240 of 325

Sort: Relevancy | Date

News Daily News

Study Suggests Routine Bridging Harmful for A-fib Patients Interrupting Anticoagulation

December 22, 2014

News Daily News

Vorapaxar podría Proteger frente a ACV Isquémicos Incidentales y Trombosis del Stent

December 04, 2014

News Daily News

Vorapaxar May Protect Against Incident Ischemic Stroke, Stent Thrombosis

December 04, 2014

News Daily News

LAA Closure With Amplatzer Appears Safe, Effective in A-fib Patients

Yael L. Maxwell

November 06, 2014

News Daily News

慢性维生素K拮抗剂使用会增加直接PCI患者的院内出血

November 02, 2014

News Daily News

El Uso Crónico de un Antagonista de la Vitamina K Aumenta las Hemorragias Intrahospitalarias en Pacientes sometidos a PCI Primarias

November 02, 2014

News Daily News

Chronic Vitamin K Antagonist Use Ups In-Hospital Bleeding Among Primary PCI Patients

November 02, 2014

News Features

Thoughtful Insights at TCT: Uncertainty Surrounds Antithrombotic Therapy in PCI Patients Who Require Anticoagulation

October 10, 2014

News Conference News TCT 2014

Thoughtful Insights at TCT: Uncertainty Surrounds Antithrombotic Therapy in PCI Patients Who Require Anticoagulation

October 10, 2014

News Daily News

2014 Guideline for NSTE-ACS Management Has New Name, Focus

September 30, 2014

TCT 475: Triple Antithrombotic Therapy Versus Dual Antiplatelet Therapy in Patients with Atrial Fibrillation Undergoing Drug-Eluting Stent Implantation

Presentation TCT 2014

TCT 475: Triple Antithrombotic Therapy Versus Dual Antiplatelet Therapy in Patients with Atrial Fibrillation Undergoing Drug-Eluting Stent Implantation

Presenter: E. Magnus Ohman, Freek W.A. Verheugt, C. Michael Gibson, Dong Oh Kang

September 15, 2014

TCT 474: Triple vs Dual Antithrombotic Therapy in Patients with Atrial Fibrillation and Acute Coronary Syndromes: The AVIATOR Registry

Presentation TCT 2014

TCT 474: Triple vs Dual Antithrombotic Therapy in Patients with Atrial Fibrillation and Acute Coronary Syndromes: The AVIATOR Registry

Presenter: E. Magnus Ohman, Freek W.A. Verheugt, C. Michael Gibson, Georgios Christodoulidis

September 15, 2014

When Should Aspirin Be Dropped From Triple Therapy? Musings on Woest and Beyond

Presentation TCT 2014

When Should Aspirin Be Dropped From Triple Therapy? Musings on Woest and Beyond

Presenter: E. Magnus Ohman, Freek W.A. Verheugt, C. Michael Gibson, Harvey D. White

September 15, 2014

Reversal of Factor Xa Inhibition

Presentation TCT 2014

Reversal of Factor Xa Inhibition

Presenter: E. Magnus Ohman, Freek W.A. Verheugt, C. Michael Gibson, Lisa K. Jennings

September 15, 2014

Edoxaban in ACS and Atrial Fibrillation: Risk/Benefit Analysis and Future Directions

Presentation TCT 2014

Edoxaban in ACS and Atrial Fibrillation: Risk/Benefit Analysis and Future Directions

Presenter: E. Magnus Ohman, Freek W.A. Verheugt, C. Michael Gibson, Michael D. Ezekowitz

September 15, 2014

Apixaban in ACS and Atrial Fibrillation: Comparison to Warfarin and Aspirin

Presentation TCT 2014

Apixaban in ACS and Atrial Fibrillation: Comparison to Warfarin and Aspirin

Presenter: E. Magnus Ohman, Freek W.A. Verheugt, C. Michael Gibson, Christopher B. Granger

September 15, 2014

Rivaroxaban in ACS and Atrial Fibrillation: Randomized Trials, Real-World Data, and Pioneering Efforts

Presentation TCT 2014

Rivaroxaban in ACS and Atrial Fibrillation: Randomized Trials, Real-World Data, and Pioneering Efforts

Presenter: E. Magnus Ohman, Freek W.A. Verheugt, C. Michael Gibson

September 15, 2014

Dabigatran in ACS and Atrial Fibrillation: MI Risks, Safety in the Elderly, and the RE-DUAL Trial

Presentation TCT 2014

Dabigatran in ACS and Atrial Fibrillation: MI Risks, Safety in the Elderly, and the RE-DUAL Trial

Presenter: E. Magnus Ohman, Freek W.A. Verheugt, C. Michael Gibson, Laura Mauri

September 15, 2014

Comparative Analysis of Warfarin and the NOACs: Differentiating Properties, Risks, and Benefits

Presentation TCT 2014

Comparative Analysis of Warfarin and the NOACs: Differentiating Properties, Risks, and Benefits

Presenter: E. Magnus Ohman, Freek W.A. Verheugt, C. Michael Gibson, Jonathan L. Halperin

September 15, 2014

The REG1 Anticoagulation System: Factor IX Inhibitor Using RNA Aptamer Technology

Presentation TCT 2014

The REG1 Anticoagulation System: Factor IX Inhibitor Using RNA Aptamer Technology

Presenter: E. Magnus Ohman, Freek W.A. Verheugt, C. Michael Gibson, A. Michael Lincoff

September 15, 2014

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.